CIM
CBPO

Contravisory Investment Management’s China Biologic Products Holdings, Inc. CBPO Stock Holding History

Contravisory Investment Management’s Portfolio CBPO Stock Details CBPO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-6
Closed – – 510
2017
Q4 		$0 Hold
6
– – ﹤0.01% 556
2017
Q3 		$1K Buy
+6
New +$577 ﹤0.01% 475

Other funds holding CBPO

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VAM
Vontobel Asset Management New York $18.1B AUM 28.09% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HSBC Holdings
HSBC Holdings London, United Kingdom $192B AUM 27.2% 1-Year Est. Return
CGI
Comgest Global Investors Paris, France $4.55B AUM 11.62% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Contravisory Investment Management's CBPO Position: Q1 2018 in Review

Contravisory Investment Management sold out of China Biologic Products Holdings, Inc. (CBPO) in Q1 2018, closing a stake of 6 shares.

Contravisory Investment Management first reported a position in CBPO in Q3 2017 and held it in 2 quarters. The position peaked at $1K in Q3 2017. 86 funds tracked by Wall St. Rank hold CBPO as of Q1 2018.

  • Contravisory Investment Management reported no remaining China Biologic Products Holdings, Inc. position as of Q1 2018 after selling out during the quarter.
  • Contravisory Investment Management sold 6 China Biologic Products Holdings, Inc. shares in Q1 2018.
  • Contravisory Investment Management first reported a position in China Biologic Products Holdings, Inc. in Q3 2017 and held it in 2 quarters.
  • Contravisory Investment Management's China Biologic Products Holdings, Inc. position peaked at $1K in Q3 2017.
  • 86 funds tracked by Wall St. Rank held China Biologic Products Holdings, Inc. as of Q1 2018.

Based on Contravisory Investment Management's 13F filing for Q1 2018, filed 9 Apr 2018.